Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
About this item
Full title
Author / Creator
Scirica, Benjamin M , Bhatt, Deepak L , Braunwald, Eugene , Steg, P. Gabriel , Davidson, Jaime , Hirshberg, Boaz , Ohman, Peter , Frederich, Robert , Wiviott, Stephen D , Hoffman, Elaine B , Cavender, Matthew A , Udell, Jacob A , Desai, Nihar R , Mosenzon, Ofri , McGuire, Darren K , Ray, Kausik K , Leiter, Lawrence A , Raz, Itamar and SAVOR-TIMI 53 Steering Committee and Investigators
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2 diabetes. Although the drug does not increase cardiovascular risk, it also does not provide cardiovascular benefit.
Type 2 diabetes mellitus doubles the risk of major cardiovascular complications...
Alternative Titles
Full title
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Authors, Artists and Contributors
Author / Creator
Bhatt, Deepak L
Braunwald, Eugene
Steg, P. Gabriel
Davidson, Jaime
Hirshberg, Boaz
Ohman, Peter
Frederich, Robert
Wiviott, Stephen D
Hoffman, Elaine B
Cavender, Matthew A
Udell, Jacob A
Desai, Nihar R
Mosenzon, Ofri
McGuire, Darren K
Ray, Kausik K
Leiter, Lawrence A
Raz, Itamar
SAVOR-TIMI 53 Steering Committee and Investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1443404511
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1443404511
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1307684
